M&A Deal Summary

Nanogen Acquires Epoch Biosciences

On December 17, 2004, Nanogen acquired life science company Epoch Biosciences from Bay City Capital

Acquisition Highlights
  • This is Nanogen’s 1st transaction in the Life Science sector.
  • This is Nanogen’s 1st transaction in the United States.
  • This is Nanogen’s 1st transaction in Washington.

M&A Deal Summary
Date 2004-12-17
Target Epoch Biosciences
Sector Life Science
Buyer(s) Nanogen
Sellers(s) Bay City Capital
Deal Type Add-on Acquisition

Target

Epoch Biosciences

Bothell, Washington, United States
Epoch Biosciences, Inc. is a biotech company focused on development and commercialization of proprietary nucleic acid chemistries for research and diagnostic applications.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nanogen

San Diego, California, United States
Category Company
Sector Medical Products
DESCRIPTION

At Nanogen, Inc., we develop diagnostic products that enable physicians to deliver improved patient care. Our products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2004) 1 of 1

Seller(S) 1

SELLER

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.

DEAL STATS #
Overall 16 of 62
Sector (Life Science) 11 of 45
Type (Add-on Acquisition) 7 of 31
State (Washington) 2 of 4
Country (United States) 15 of 59
Year (2004) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-12-06 SemBioSys Genetics

Calgary, Alberta, Canada

SemBioSys Genetics, Inc. is a developer of high value proteins and oil body based products for personal care, nutrition and pharmaceutical industries using its proprietary oil body/oleosin technology.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-02-05 Syrrx

San Diego, California, United States

Syrrx, Inc. is a structural genomics company.

Sell -
Mergr

Product

Company

Legal